Navigation Links
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
Date:9/7/2007

ncies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

COMPANY CONTACTS MEDIA CONTACT

Russell Skibsted Susan Neath

SVP & Chief Business Officer Porter Novelli Life Sciences

619-849-6007

Paul Arndt

Manager, Investor Relations

949-788-6700


'/>"/>
SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tech Digest: Firstlogic, Fiserv, Red Prairie, Spectrum Brands, Associated Bank
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
5. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
6. CIOs looking to hire more IT workers in second quarter
7. DNASTAR catches second wave of sequencing
8. 9 tips for making 90 seconds count in an investment pitch
9. City of Hope adds second TomoTherapy system
10. UW-Madison hybrid-vehicle team places second nationally
11. Just one nanosecond: Clocking events at the nanoscale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Nov. 10, 2010 Celsion Corporation (Nasdaq: ... that is leveraging its heat sensitive liposomal platform to ... announced that it has changed  the date and time ... Veteran,s Day Holiday on November 11, 2010.  The SEC,s ...
... Biodesix Inc. announced today that the company has ... existing investors. The Series C round, which included 5 ... company,s first product VeriStrat®, a serum proteomic test that ... lung cancer (NSCLC). Existing shareholders of the company provided ...
... StemCellRegenMed, Inc. announces that a new stem cell gene ... month old child with Tay-Sachs disease on November 2, 2010. ... parents of Jewish heritage and in very rare cases families ... U.S.A. The children appear normal at birth but about six ...
Cached Biology Technology:Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010 2Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... material -- in particular, dog fecal material -- may constitute ... wintertime air, says a new University of Colorado Boulder study. ... Midwestern cities in the experiment, two cities had significant quantities ... being the most likely source. "We found unexpectedly ...
... life-saving to have a warning sign before a structural system ... size, having a sign that,s easy to read is a challenge. ... University of Pennsylvania and Duke University bioengineers and chemists, such warning ... The study was conducted by professor Daniel Hammer ...
... Women and men experience pain, particularly chronic pain, ... pain also differs between women and men. While it ... analgesics are more effective in women than men, the ... Narcotic analgesics decrease pain by activating opioid receptors, which ...
Cached Biology News:New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 2New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 3Penn molecular scientists develop color-changing stress sensor 2Penn molecular scientists develop color-changing stress sensor 3SUNY Downstate researchers identify possible new targets for treating pain in women 2